CE Marking: Yes


Medytox
Neuramis® Deep Lidocaine 1 x 1ml
Article: Neuramis® Deep Lidocaine
Manufacturer: Medytox
Concentration: 20 mg/ml
Package contents: 1 x 1ml
Needle/cannulas: 2 x 27G ½
Choose options
Article: Neuramis® Deep Lidocaine
Manufacturer: Medytox
Concentration: 20 mg/ml
Package contents: 1 x 1ml
Needle/cannulas: 2 x 27G ½
Article: Neuramis® Deep Lidocaine
Manufacturer: Medytox
Concentration: 20 mg/ml
Package contents: 1 x 1ml
Needle/cannulas: 2 x 27G ½
Neuramis® Deep Lidocaine
Neuramis Deep Lidocaine is an advanced Dermal Filler specifically developed for the correction of moderate to deep wrinkles as well as for volumizing the face. Neuramis Deep Lidocaine combines the benefits of cross-linked hyaluronic acid with the comfort of a local anesthetic, Lidocaine, to ensure a pain-free and effective treatment.
Neuramis Deep Lidocaine is based on cross-linked hyaluronic acid, produced using the innovative SHAPE™ Technology. This technology ensures a consistent particle size and high purity, minimizing the risk of side effects and providing long-lasting results. Additionally, the product contains 0.3% Lidocaine, a proven local anesthetic that significantly enhances treatment comfort.
AREAS OF APPLICATION
- Nasolabial folds
- Marionette lines
- Lip volume and contour
- Cheek volume
What Makes Neuramis® Deep Lidocaine Unique
- Long-lasting results: The advanced cross-linking technology ensures results that last up to 12 months.
- High comfort: The included Lidocaine allows for a pain-free treatment and enhances patient experience.
- Safety and purity: The manufacturing method ensures high purity and biocompatibility, reducing the risk of allergic reactions and side effects.
- Easy and even application: The smooth gel texture allows for precise injections and natural results.
Medytox
Medytox is a leading global biopharmaceutical company, known for its innovative research and development. Since the introduction of Botulinum Toxin Type A Meditoxin® in 2006, Medytox has experienced significant growth, with nearly 40% market share in Korea since 2009.